Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE36.6800
- TODAY'S CHANGE (%)0.5600 (1.5504%)
- Bid / Lots36.6500/ 2
- Ask / Lots36.7500/ 4
- Open / Previous Close36.2800 / 36.1200
- Day Range
- 52 Week Range
- Volume249,351
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1580 | 36.28 |
| 09:34 ET | 475 | 36.19 |
| 09:39 ET | 107 | 36.3 |
| 09:45 ET | 428 | 36.45 |
| 09:50 ET | 249 | 36.52 |
| 09:52 ET | 100 | 36.4 |
| 09:54 ET | 200 | 36.4 |
| 09:56 ET | 300 | 36.4 |
| 09:57 ET | 300 | 36.27 |
| 09:59 ET | 101 | 36.39 |
| 10:03 ET | 1317 | 36.185 |
| 10:06 ET | 3300 | 36.14 |
| 10:08 ET | 3072 | 36.2 |
| 10:10 ET | 3500 | 36.01 |
| 10:12 ET | 1590 | 36.135 |
| 10:14 ET | 300 | 36.14 |
| 10:15 ET | 1652 | 36.02 |
| 10:17 ET | 200 | 36.095 |
| 10:21 ET | 454 | 36.1 |
| 10:24 ET | 700 | 36.03 |
| 10:26 ET | 200 | 35.97 |
| 10:28 ET | 2400 | 35.96 |
| 10:30 ET | 15239 | 36.02 |
| 10:32 ET | 4186 | 36.07 |
| 10:33 ET | 21882 | 36.36 |
| 10:35 ET | 100 | 36.23 |
| 10:37 ET | 8911 | 36.12 |
| 10:39 ET | 1258 | 36.145 |
| 10:42 ET | 916 | 36.18 |
| 10:44 ET | 400 | 36.205 |
| 10:46 ET | 317 | 36.2 |
| 10:48 ET | 300 | 36.17 |
| 10:50 ET | 400 | 36.115 |
| 10:51 ET | 100 | 36.115 |
| 10:53 ET | 100 | 36.115 |
| 10:55 ET | 1327 | 36.16 |
| 10:57 ET | 1927 | 36.165 |
| 11:00 ET | 210 | 36.15 |
| 11:02 ET | 200 | 36.1 |
| 11:04 ET | 100 | 36.12 |
| 11:08 ET | 3133 | 36.24 |
| 11:09 ET | 408 | 36.2475 |
| 11:11 ET | 500 | 36.265 |
| 11:15 ET | 1100 | 36.345 |
| 11:18 ET | 4306 | 36.42 |
| 11:20 ET | 200 | 36.46 |
| 11:22 ET | 914 | 36.24 |
| 11:27 ET | 1785 | 36.22 |
| 11:29 ET | 100 | 36.22 |
| 11:31 ET | 3052 | 36.3 |
| 11:33 ET | 3644 | 36.3 |
| 11:36 ET | 415 | 36.285 |
| 11:38 ET | 2300 | 36.255 |
| 11:40 ET | 3910 | 36.43 |
| 11:42 ET | 100 | 36.57 |
| 11:44 ET | 431 | 36.56 |
| 11:47 ET | 100 | 36.555 |
| 11:49 ET | 100 | 36.53 |
| 11:51 ET | 100 | 36.56 |
| 11:54 ET | 600 | 36.51 |
| 11:56 ET | 217 | 36.495 |
| 11:58 ET | 300 | 36.49 |
| 12:02 ET | 907 | 36.45 |
| 12:03 ET | 200 | 36.5 |
| 12:05 ET | 100 | 36.45 |
| 12:09 ET | 310 | 36.51 |
| 12:12 ET | 434 | 36.525 |
| 12:14 ET | 200 | 36.56 |
| 12:16 ET | 100 | 36.51 |
| 12:18 ET | 969 | 36.56 |
| 12:20 ET | 977 | 36.605 |
| 12:21 ET | 100 | 36.56 |
| 12:23 ET | 100 | 36.6 |
| 12:25 ET | 1000 | 36.49 |
| 12:30 ET | 624 | 36.56 |
| 12:32 ET | 200 | 36.545 |
| 12:36 ET | 287 | 36.55 |
| 12:38 ET | 626 | 36.495 |
| 12:39 ET | 8951 | 36.42 |
| 12:41 ET | 702 | 36.3999 |
| 12:43 ET | 1660 | 36.395 |
| 12:45 ET | 1312 | 36.405 |
| 12:48 ET | 700 | 36.42 |
| 12:50 ET | 2019 | 36.45 |
| 12:52 ET | 200 | 36.45 |
| 12:54 ET | 100 | 36.47 |
| 12:56 ET | 100 | 36.44 |
| 12:59 ET | 100 | 36.42 |
| 01:01 ET | 200 | 36.45 |
| 01:06 ET | 2094 | 36.46 |
| 01:08 ET | 400 | 36.455 |
| 01:10 ET | 2830 | 36.405 |
| 01:12 ET | 100 | 36.38 |
| 01:14 ET | 1888 | 36.465 |
| 01:15 ET | 290 | 36.45 |
| 01:17 ET | 1257 | 36.405 |
| 01:21 ET | 1582 | 36.425 |
| 01:24 ET | 200 | 36.4 |
| 01:26 ET | 3294 | 36.455 |
| 01:28 ET | 300 | 36.48 |
| 01:32 ET | 100 | 36.48 |
| 01:33 ET | 300 | 36.47 |
| 01:37 ET | 220 | 36.46 |
| 01:39 ET | 500 | 36.45 |
| 01:42 ET | 1648 | 36.515 |
| 01:44 ET | 600 | 36.565 |
| 01:46 ET | 100 | 36.54 |
| 01:48 ET | 200 | 36.54 |
| 01:50 ET | 900 | 36.53 |
| 01:51 ET | 300 | 36.54 |
| 01:53 ET | 400 | 36.51 |
| 01:57 ET | 1219 | 36.49 |
| 02:00 ET | 1200 | 36.45 |
| 02:02 ET | 100 | 36.42 |
| 02:04 ET | 1108 | 36.445 |
| 02:06 ET | 100 | 36.45 |
| 02:08 ET | 1138 | 36.51 |
| 02:09 ET | 1002 | 36.515 |
| 02:11 ET | 388 | 36.575 |
| 02:13 ET | 205 | 36.56 |
| 02:18 ET | 490 | 36.58 |
| 02:20 ET | 254 | 36.57 |
| 02:24 ET | 400 | 36.46 |
| 02:26 ET | 100 | 36.46 |
| 02:27 ET | 100 | 36.485 |
| 02:31 ET | 400 | 36.45 |
| 02:33 ET | 600 | 36.45 |
| 02:36 ET | 500 | 36.42 |
| 02:38 ET | 301 | 36.45 |
| 02:40 ET | 1750 | 36.44 |
| 02:42 ET | 1262 | 36.44 |
| 02:44 ET | 200 | 36.45 |
| 02:47 ET | 600 | 36.455 |
| 02:51 ET | 311 | 36.48 |
| 02:54 ET | 200 | 36.45 |
| 02:56 ET | 200 | 36.46 |
| 03:00 ET | 200 | 36.46 |
| 03:02 ET | 1933 | 36.49 |
| 03:03 ET | 3290 | 36.47 |
| 03:05 ET | 363 | 36.5 |
| 03:07 ET | 750 | 36.48 |
| 03:09 ET | 2109 | 36.5 |
| 03:12 ET | 1091 | 36.55 |
| 03:14 ET | 831 | 36.575 |
| 03:16 ET | 417 | 36.545 |
| 03:18 ET | 106 | 36.54 |
| 03:20 ET | 100 | 36.555 |
| 03:21 ET | 1660 | 36.56 |
| 03:23 ET | 1717 | 36.57 |
| 03:25 ET | 5616 | 36.675 |
| 03:27 ET | 3047 | 36.68 |
Jun 18, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:59AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.7B | -13.5x | --- |
MoonLake Immunotherapeutics | 2.7B | -56.0x | --- |
SpringWorks Therapeutics Inc | 2.8B | -7.2x | --- |
Geron Corp | 2.6B | -13.0x | --- |
Biohaven Ltd | 3.0B | -5.0x | --- |
IDEAYA Biosciences Inc | 2.5B | -17.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
